Skip to main content

Revance Therapeutics, Inc.

RVNCDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001479290

Revance Therapeutics, Inc. was delisted in 2025; its insiders filed their last Form 4 on Feb 6, 2025; 174 institutions reported holding it in 13F filings for Q4 2024, worth $249.2M in total; Fairfax Financial was the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Revance Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Revance Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Revance Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Beraud JillDirector0Feb 6, 20250
Foley Mark JPresident & CEO0Feb 6, 20250
Gangolli Julian SDirector0Feb 6, 20250
Russell Angus C.Director0Feb 6, 20250
Ware Olivia CDirector0Feb 6, 20250
Schilke TobinCFO0Feb 6, 20250
Coric VladDirector0Feb 6, 20250
Nolet ChrisDirector0Feb 6, 20250
Hollander DavidCMO & Global Therapeutics Lead0Feb 6, 20250
Moxie DwightCLO & GC0Feb 6, 20250
Kolaja Carey OConnorDirector0Feb 6, 20250
Jordan EricaChief Commercial Officer0Feb 6, 20250
Sjuts Dustin SPresident167,550Mar 19, 20240
Vickers Philip J.Director29,722May 13, 20220
Joshi AbhayCOO, President of R&D120,708Mar 17, 20220
Rankin AubreyDirector94,091Mar 17, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 19, 2024 (view filing)Nov 181 dayHollander DavidCMO & Global Therapeutics LeadSSale−3.91K$4.17−$16.3K−3.6%104.9K after
Apr 17, 2024 (view filing)Apr 161 dayJordan EricaChief Commercial OfficerSSale−2.39K$3.80−$9.09K−2.0%114.9K after
Mar 19, 2024 (view filing)Mar 181 daySjuts Dustin SPresidentSSale−9.21K$5.04−$46.4K−5.2%167.6K after
Mar 19, 2024 (view filing)Mar 181 dayMoxie DwightCLO & GCSSale−8.13K$5.04−$41.0K−5.6%137.8K after
Mar 19, 2024 (view filing)Mar 181 daySchilke TobinCFOSSale−9.36K$5.04−$47.2K−4.6%192.7K after
Mar 8, 2024 (view filing)Mar 62 daysFoley Mark JCEOPPurchase+30.0K$6.98+$209.4K+3.0%1.02M after
Sep 7, 2023 (view filing)Sep 5-62 daysMoxie DwightSVP, GC & SecretarySSale−34.9K$17.57−$612.5K−44.2%44.1K after2 lots10b5-1
Aug 4, 2023 (view filing)Aug 31 dayFoley Mark JCEOSSale−26.3K$22.57−$593.1K−3.0%840.4K after10b5-1
Jul 5, 2023 (view filing)Jul 32 daysSchilke TobinCFOSSale−1.70K$25.04−$42.6K−2.1%79.9K after10b5-1
Jul 5, 2023 (view filing)Jul 32 daysFoley Mark JCEOSSale−26.3K$24.94−$655.4K−2.9%866.7K after10b5-1
Jun 20, 2023 (view filing)Jun 155 daysKolaja Carey OConnorDirectorSSale−2.50K$28.24−$70.6K−13.1%16.6K after10b5-1
Jun 13, 2023 (view filing)Jun 94 daysSjuts Dustin SPresidentSSale−5.00K$30.82−$154.1K−3.3%147.3K after10b5-1
Jun 13, 2023 (view filing)Jun 94 daysFoley Mark JCEOSSale−31.3K$30.72−$960.9K−3.4%891.9K after10b5-1
Jun 5, 2023 (view filing)Jun 1-24 daysSchilke TobinCFOSSale−3.20K$30.64−$98.1K−3.8%80.8K after2 lots10b5-1
May 16, 2023 (view filing)May 151 dayMoxie DwightSVP, GC & SecretarySSale−21.4K$34.55−$739.4K−23.6%69.2K after
May 16, 2023 (view filing)May 151 daySchilke TobinCFOSSale−21.4K$34.55−$739.4K−20.3%84.0K after
May 16, 2023 (view filing)May 151 dayFoley Mark JCEOSSale−70.4K$34.55−$2.43M−7.1%923.2K after
May 16, 2023 (view filing)May 151 daySjuts Dustin SPresidentSSale−21.0K$34.55−$726.1K−12.1%152.3K after
May 2, 2023 (view filing)May 11 daySchilke TobinCFOSSale−3.20K$31.70−$101.5K−4.8%63.1K after10b5-1
Apr 4, 2023 (view filing)Apr 31 daySchilke TobinCFOSSale−3.20K$32.15−$102.9K−4.6%66.3K after10b5-1
Mar 9, 2023 (view filing)Mar 9Same dayMoxie DwightSVP, GC & SecretarySSale−18.5K$31.59−$584.3K−25.0%55.5K after
Mar 9, 2023 (view filing)Mar 9Same daySchilke TobinCFOSSale−18.5K$31.59−$585.0K−20.2%73.2K after
Mar 9, 2023 (view filing)Mar 9Same daySjuts Dustin SPresidentSSale−21.5K$31.59−$679.4K−14.8%123.9K after
Mar 9, 2023 (view filing)Mar 9Same dayFoley Mark JCEOSSale−70.4K$31.59−$2.22M−7.9%823.4K after
Mar 2, 2023 (view filing)Mar 11 daySchilke TobinCFOSSale−3.20K$33.50−$107.2K−6.1%49.4K after
Feb 2, 2023 (view filing)Feb 11 daySchilke TobinCFOSSale−3.20K$34.60−$110.8K−5.5%54.7K after
Jan 23, 2023 (view filing)Jan 203 daysSchilke TobinCFOSSale−1.00K$31.00−$31.0K−1.7%57.9K after
Jan 10, 2023 (view filing)Jan 91 daySchilke TobinCFOSSale−3.70K$27.16−$100.5K−5.9%58.9K after3 lots
Sep 16, 2022 (view filing)Sep 142 daysMoxie DwightSVP, GC & SecretarySSale−11.0K$27.07−$297.8K−25.8%31.7K after
Dec 15, 2021 (view filing)Dec 132 daysRussell Angus C.DirectorPPurchase+6.40K$15.74+$100.7K+31.2%26.9K after
Dec 6, 2021 (view filing)Dec 33 daysRankin AubreyPresident, Innovation & TechPPurchase+30.0K$14.43+$432.9K+45.8%95.5K after
Nov 29, 2021 (view filing)Nov 29Same dayFoley Mark JCEOPPurchase+40.0K$12.90+$516.0K+56.4%110.9K after
Sep 28, 2021 (view filing)Sep 271 dayMoxie DwightSVP, GC & SecretarySSale−1.68K$30.00−$50.3K−3.4%47.8K after
Aug 17, 2021 (view filing)Aug 161 dayRankin AubreyPresident, Innovation & TechSSale−9.36K$26.34−$246.6K−12.5%65.5K after
Jul 30, 2021 (view filing)Jul 282 daysRankin AubreyPresident, Innovation & TechSSale−54.3K$30.06−$1.63M−26.0%154.3K after2 lots
Jul 28, 2021 (view filing)Jul 262 daysRankin AubreyPresident, Innovation & TechSSale−55.4K$29.72−$1.65M−13.5%355.9K after